LBL-043

N/A

Report date: 2026/03/19 17:15:03

Base Information

Drug NameLBL-043
Drug Alias NameLBL-043
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4Anti-CD3
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4T cell surface glycoprotein CD3
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A